News and Announcements
Actinogen Medical CEO Interview
- Published September 23, 2016 11:18AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment. The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.
Please listen to Dr. Bill Ketelbey, Founder and CEO & Managing Director of Actinogen Medical below.
Executive Interviews
7 Reasons Bitcoin Shines as the Apex of Technological Beauty
In the ever-evolving landscape of technology, Bitcoin stands as a beacon of innovation, not just in currency but in the philosophy of financial freedom and digital security. Here’s why Bitcoin is considered the zenith of technological beauty. 1. Decentralization Bitcoin’s decentralized nature is its philosophical cornerstone. It operates on a network where no single entity […]
Fun Facts about Bitcoin and Crypto
Crypto Investment Trends At Emergence 2024, I outlined how when it comes to innovation, first, innovators equal the incumbent, then they 10X beyond it. To celebrate this trend, here are 7 fun facts you may not know about the rise of Bitcoin and how it compares with incumbents, plus a fun fact about Coinbase: 1. […]
The Innovator Overtaking the Incumbent: A New Era in Mobility
The disruptor becomes the disrupted. The ride-sharing industry, once dominated by giants like Uber and Lyft, is witnessing a seismic shift. Waymo’s Ascendance With its relentless focus on autonomous driving technology, Waymo has steadily climbed the ranks. From a modest beginning, it’s now poised to challenge the market leaders. The graph beautifully illustrates this trajectory, […]
Backed By Leading Investment Groups and Family Offices
